At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 627 enrolled
Drug / intervention
tanezumab +3 morebiological
Likely dose
tanezumab 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE HIP.
In Brief
A Phase 3 clinical trial evaluating tanezumab and Placebo for Arthritis and 2 related conditions. Completed, enrolled 627 participants across 99 sites.
Detailed Summary
The purpose of this study is to test the efficacy and safety of 3 doses of tanezumab in osteoarthritis of the hip in patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Osteoarthritis, Osteoarthritis, Hip
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartNov 2008
Primary CompletionMar 2010
Study CompletionAug 2010
TodayJul 2026
First PostedSep 1, 2008
Enrollment StartNov 17, 2008
Primary CompletionMar 15, 2010
Study CompletionAug 13, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.8 years ago
Interventions
tanezumabbiological
Tanezumab 10 mg IV every 8 weeks
tanezumabbiological
Tanezumab 5mg IV every 8 weeks
tanezumabbiological
Tanezumab 2.5 mg IV every 8 weeks.
Placebobiological
Placebo to match tanezumab IV every 8 weeks